EWTX Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of 4.09%. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Edwards Lifesciences Corp.'s return on equity of 10.27%.

Edgewise Therapeutics, Inc. has a consensus price target of $41.08, signalling upside risk potential of 23.26%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.93 which suggests that it could grow by 19.59%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Edgewise Therapeutics, Inc. is more attractive than Edwards Lifesciences Corp..

Edgewise Therapeutics, Inc. has a beta of 0.240, which suggesting that the stock is 76.023% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.437%.

Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.

Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Edgewise Therapeutics, Inc.'s net income of -$50.2M is lower than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Edwards Lifesciences Corp.'s PE ratio is 44.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 7.80x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Glaukos Corp. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of -93.39%. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Glaukos Corp.'s return on equity of -25.22%.

Edgewise Therapeutics, Inc. has a consensus price target of $41.08, signalling upside risk potential of 23.26%. On the other hand Glaukos Corp. has an analysts' consensus of $138.75 which suggests that it could grow by 23.04%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Edgewise Therapeutics, Inc. is more attractive than Glaukos Corp..

Edgewise Therapeutics, Inc. has a beta of 0.240, which suggesting that the stock is 76.023% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.780, suggesting its less volatile than the S&P 500 by 21.977%.

Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Glaukos Corp. quarterly revenues of $143.1M. Edgewise Therapeutics, Inc.'s net income of -$50.2M is higher than Glaukos Corp.'s net income of -$133.7M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 12.72x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of 34.4%. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Eli Lilly & Co.'s return on equity of 104.39%.

Edgewise Therapeutics, Inc. has a consensus price target of $41.08, signalling upside risk potential of 23.26%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Eli Lilly & Co. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Eli Lilly & Co. is more attractive than Edgewise Therapeutics, Inc..

Edgewise Therapeutics, Inc. has a beta of 0.240, which suggesting that the stock is 76.023% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Edgewise Therapeutics, Inc.'s net income of -$50.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Nuvalent, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of --. Edgewise Therapeutics, Inc.'s return on equity of -32.79% beat Nuvalent, Inc.'s return on equity of -41.59%.

Edgewise Therapeutics, Inc. has a consensus price target of $41.08, signalling upside risk potential of 23.26%. On the other hand Nuvalent, Inc. has an analysts' consensus of $142.39 which suggests that it could grow by 35.06%. Given that Nuvalent, Inc. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Nuvalent, Inc. is more attractive than Edgewise Therapeutics, Inc..

Edgewise Therapeutics, Inc. has a beta of 0.240, which suggesting that the stock is 76.023% less volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.

Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Nuvalent, Inc. quarterly revenues of --. Edgewise Therapeutics, Inc.'s net income of -$50.2M is higher than Nuvalent, Inc.'s net income of -$118.7M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.